Compare NXJ & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NXJ | NMRA |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 554.0M |
| IPO Year | N/A | 2023 |
| Metric | NXJ | NMRA |
|---|---|---|
| Price | $12.02 | $2.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $6.57 |
| AVG Volume (30 Days) | 90.7K | ★ 732.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | N/A | ★ 57.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.01 | $0.62 |
| 52 Week High | $12.90 | $3.65 |
| Indicator | NXJ | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 23.20 | 35.39 |
| Support Level | $11.22 | $2.35 |
| Resistance Level | $12.76 | $2.58 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 6.12 | 5.86 |
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.